NCT03634098View on ClinicalTrials.gov

Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics

NACompletedINTERVENTIONAL

Enrollment

970

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

July 31, 2022

Study Completion Date

September 30, 2022

Conditions

Type2 Diabetes

Interventions

DEVICE

new quantitative imaging techniques with contast products

magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue

DIAGNOSTIC_TEST

blood sample

extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data

DIAGNOSTIC_TEST

second generation tests

second generation tests NIT-NASHr et NIT-A2F2

Trial Locations (1)

Unknown

Hôpital Beaujon, Clichy

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03634098 - Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics | Biotech Hunter | Biotech Hunter